CoreMed Invites You to the 7th Future Healthcare 100 Summit 2023

Over the past decade, the global healthcare industry has undergone significant restructuring, a transformation accelerated by the COVID-19 pandemic since 2020. Having withstood the compounded challenges of global upheavals and the century-defining pandemic from 2020 to 2022, 2023 marked the first year for implementing the strategic arrangements outlined at the 20th National Congress of the Communist Party of China, as well as a critical year for advancing the 14th Five-Year Plan. Only by accumulating strength, demonstrating the resilience to “stand firm amidst countless trials” and the character to “press forward despite mounting difficulties,” and reinforcing self-confidence through decisive action, can innovators in the healthcare sector successfully deliver on the era’s mandate for high-quality development in healthcare.

The 7th Future Healthcare Top 100 Conference, themed “No Boundaries,” was organized by VCBeat and Eggshell Institute, in strategic partnership with Shanghai Zhangjiang Group. Integrating cutting-edge academic and research insights, comprehensive industry perspectives, and keen awareness of capital trends, the conference was held at the Shanghai Zhangjiang Science Hall from May 5–7, 2023. It brought together industry peers to explore the innovative future of the broader health sector and embark on a new journey in healthcare innovation.

After six successful editions, the conference has become China’s largest and most information-rich ecosystem summit integrating industry and capital within the healthcare innovation sector. Centered on “connecting global wisdom, sharing cutting-edge technologies, inspiring the technological future, and focusing on venture capital interaction,” it sets the direction for innovation and investment in China’s healthcare field. The 7th Future Healthcare Top 100 Conference in 2023 will feature three major summits, over 20 thematic forums covering specialized sectors, the release of the Future Healthcare Top 100 series rankings and awards, more than ten thematic reports, and seven concurrent networking events. Distinguished guests and attendees from government agencies, academicians and scientists, clinical and research experts, Fortune 500/listed companies, top-tier investment institutions and securities firms, as well as innovative healthcare enterprises, will be invited to participate. This gathering of minds aims to provide insights to the industry and usher in a new future.

“Ask only of courage, ask only of blossoming, ask not of west or east” makes a powerful arrival!

Against the backdrop of an aging population, China’s vascular interventional device market remains in a phase of steady growth. In 2021, the market size reached RMB 43.2 billion, representing a year-on-year increase of 3.35%. Although the growth rate slowed due to the national centralized procurement of coronary stents implemented in 2021, the market landscape is evolving. Industry growth drivers are shifting from cardiovascular interventions to neurointerventional and peripheral vascular intervention markets. Consequently, the market size of vascular interventional devices in China is expected to maintain its upward trajectory.

The Future Healthcare Top 100 Conference also features a Frontier Innovation Forum on Vascular Intervention, which will invite clinical experts, leading industry enterprises, and investment institutions to comprehensively discuss technological innovations, research and current clinical practices, product landscapes, and development trends in vascular intervention therapy from their respective perspectives.

Recently, Claris’s next-generation embolic microsphere product, independently developed with full intellectual property rights, has received market approval from the National Medical Products Administration (NMPA). This is the first microsphere product in China to be validated through pre-market randomized controlled trial (RCT) clinical studies. The product not only overcomes critical technological bottlenecks in China’s 100% patent-protected landscape for embolic and drug-eluting microspheres, but also features a creatively developed new generation of “biomimetic core-shell structure” embolic microspheres that have achieved industrial-scale production, effectively filling the gap in domestically produced technologies and products for transarterial chemoembolization (TACE) in interventional tumor therapy. Ms. Sun Peng, Co-founder and General Manager of Claris Medical, was invited to attend the conference and will deliver a keynote speech at the Frontier Innovation Forum on Vascular Intervention. She will share the stage with representatives from related enterprises to discuss how “therapy reading” drives innovative development in the field of vascular interventional tumor therapy.

(All-Access Pass: Enjoy 30+ Forums)